Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers
Authors
Keywords
-
Journal
CELL DEATH AND DIFFERENTIATION
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-09-18
DOI
10.1038/s41418-021-00869-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance
- (2020) Andriy Marusyk et al. CANCER CELL
- Targeting apoptosis in cancer therapy
- (2020) Benedito A. Carneiro et al. Nature Reviews Clinical Oncology
- Cell Death in the Origin and Treatment of Cancer
- (2020) Andreas Strasser et al. MOLECULAR CELL
- The National Lung Matrix Trial of personalized therapy in lung cancer
- (2020) Gary Middleton et al. NATURE
- Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology
- (2019) Amit J. Sabnis et al. TRENDS IN MOLECULAR MEDICINE
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- (2019) O Hamid et al. ANNALS OF ONCOLOGY
- The great escape: tumour cell plasticity in resistance to targeted therapy
- (2019) Soufiane Boumahdi et al. NATURE REVIEWS DRUG DISCOVERY
- Apoptosis and Clearance of Apoptotic Cells
- (2018) Shigekazu Nagata Annual Review of Immunology
- CDK9 inhibitors in acute myeloid leukemia
- (2018) Silvia Boffo et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Kinase-targeted cancer therapies: progress, challenges and future directions
- (2018) Khushwant S. Bhullar et al. Molecular Cancer
- Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
- (2018) Georgios Vlachogiannis et al. SCIENCE
- BCL-2 inhibition in AML: an unexpected bonus?
- (2018) Marina Konopleva et al. BLOOD
- BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
- (2018) Delphine Merino et al. CANCER CELL
- Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
- (2018) Sunilkumar Kakadia et al. OncoTargets and Therapy
- The target landscape of clinical kinase drugs
- (2017) Susan Klaeger et al. SCIENCE
- CDK9 is a prognostic marker and therapeutic target in pancreatic cancer
- (2017) Anna-Laura Kretz et al. TUMOR BIOLOGY
- Targeting cell death signalling in cancer: minimising ‘Collateral damage’
- (2016) Joanna L Fox et al. BRITISH JOURNAL OF CANCER
- Onto better TRAILs for cancer treatment
- (2016) D de Miguel et al. CELL DEATH AND DIFFERENTIATION
- Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment
- (2016) Yinshi Huang et al. CLINICAL CANCER RESEARCH
- Targeting CDK9: a promising therapeutic opportunity in prostate cancer
- (2016) Muhammed H Rahaman et al. ENDOCRINE-RELATED CANCER
- Genetics and biology of pancreatic ductal adenocarcinoma
- (2016) Haoqiang Ying et al. GENES & DEVELOPMENT
- Combine and conquer: challenges for targeted therapy combinations in early phase trials
- (2016) Juanita S. Lopez et al. Nature Reviews Clinical Oncology
- Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
- (2015) Joan Montero et al. CELL
- Targeting TRAIL in the treatment of cancer: new developments
- (2015) Bora Lim et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers
- (2015) Giorgio G. Galli et al. MOLECULAR CELL
- Tissue-based map of the human proteome
- (2015) M. Uhlen et al. SCIENCE
- Getting TRAIL back on track for cancer therapy
- (2014) J Lemke et al. CELL DEATH AND DIFFERENTIATION
- TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells
- (2014) M H Tuthill et al. ONCOGENE
- Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1
- (2013) J Lemke et al. CELL DEATH AND DIFFERENTIATION
- Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis
- (2013) Meritxell Huch et al. EMBO JOURNAL
- Isolation, culture and genetic manipulation of mouse pancreatic ductal cells
- (2013) Maximilian Reichert et al. Nature Protocols
- Cyclin-dependent kinase inhibitors move into Phase III
- (2012) Malini Guha NATURE REVIEWS DRUG DISCOVERY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib
- (2010) D Lecis et al. BRITISH JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started